Clinical trials: Alzheimer Disease 3
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial)…
- Trial name
- NCT04468659
- Testing
- Lecanemab
- Where
- 107 sites in United States, Australia and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease
This study is a comparison of 3 learning techniques, Errorless learning, modelling and trial and error, in the relearning of IADL of Alzheimer patients from mild to moderately severe dementia.
- Trial name
- C3LM-ILAD (NCT01095718)
- Testing
- Errorless Learning, Modeling, Trial and Error
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Department of Clinical Research and Innovation
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
Alzheimer Disease, Dementia of Alzheimer Type
DMB-I in the Treatment of Alzheimer Type Dementia
The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
- Trial name
- NCT06292351
- Testing
- DMB-I (Dimebon)
- Where
- 7 sites in Russia
- Volunteers
- 133 people
- Sponsor
- Bigespas LTD
Alzheimer Disease
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks.
- Trial name
- NCT05026866
- Testing
- Donanemab
- Where
- 216 sites in United States, Japan and 1 more
- Volunteers
- 2,996 people
- Sponsor
- Eli Lilly and Company
Agitation in Patients With Dementia of the Alzheimer's Type
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National…
- Trial name
- NCT02442765
- Testing
- AVP-786
- Where
- 126 sites in United States, Estonia and 4 more
- Volunteers
- 387 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease, Dementia
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo.
- Trial name
- NCT00322036
- Testing
- MPC-7869
- Where
- 92 sites in United States, Belgium and 10 more
- Volunteers
- 800 people
- Sponsor
- Myrexis Inc.
Alzheimer Disease
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD)…
- Trial name
- NCT03823404
- Testing
- COR388 capsule
- Where
- 93 sites in United States, France and 4 more
- Volunteers
- 643 people
- Sponsor
- Cortexyme Inc.
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969136
- Testing
- Drug: EVP-6124
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 403 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00667810
- Testing
- bapineuzumab
- Where
- 346 sites in United States, Argentina and 24 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Dementia, Alzheimer's Disease
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
To Determine the the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology
- Trial name
- NCT01886820
- Testing
- [18F]NAV4694
- Where
- 15 sites in United States
- Volunteers
- 290 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer Disease
Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production
Phase 1, Single-center, Open-label Study, Healthy Adult Male Subjects. Part 1:Single-dose, Placebo-controlled, 3-Way Crossover PK Study Part 2: Single dose 2-way comparator PK Study
- Trial name
- NCT03971123
- Testing
- Tricaprilin
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cerecin
Down Syndrome (DS), Alzheimer's Disease (AD)
Adapting RDAD for DS
The goal of this clinical trial is to observe feasibility and initial efficacy of a remotely delivered exercise and dementia caregiving intervention in older adults with Down syndrome and their caregivers.
- Trial name
- CareFit DS/AD (NCT07425769)
- Testing
- Remote Exercise Sessions, Caregiver Education Sessions
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Alzheimer Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Trial name
- NCT07011732
- Testing
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule
- Where
- 162 sites in United States, Argentina and 13 more
- Volunteers
- 426 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
- Trial name
- NCT05575076
- Testing
- Simufilam
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 1,081 people
- Sponsor
- Cassava Sciences, Inc.
Dementia, Alzheimer Disease
Effectiveness of a 3-month Individual Reminiscence Therapy Program in Older Adults With Alzheimer's Disease
This research aims to evaluate the effectiveness of individual Reminiscence Therapy (RT) program, using a simple reminiscence format, to improve the overall cognitive function, mood, and quality of life (QoL) of older adults with…
- Conditions
- Dementia, Alzheimer Disease, Cognitive Impairment
- Trial name
- NCT06812442
- Testing
- Reminiscence therapy
- Where
- 4 sites in Portugal
- Volunteers
- 40 people
- Sponsor
- Rsocialform - Geriatria, Lda
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's…
- Trial name
- NCT06126224
- Testing
- KarXT
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 500 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Alzheimer's Disease
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
This is a Phase II, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of Rasagiline in the regional brain metabolism on 18F-2-fluoro-2-deoxy-D-glucose…
- Trial name
- R2 (NCT02359552)
- Testing
- Rasagiline
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease, Mild Cognitive Impairment
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients.
- Trial name
- NCT06595030
- Testing
- Active Lighting Intervention, Control Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Icahn School of Medicine at Mount Sinai